Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-08-19, Stock:LLY, The news for the past five days is as follows:
2019-08-12: NEWS1: Noteworthy ETF Outflows: IVW, KO, LLY, FIS.NEWS2: Noteworthy ETF Outflows: IVW, KO, LLY, FIS.
2019-08-13: NEWS1: Lilly's Psoriasis Drug Found Superior To J&J's Tremfya In Phase 4 Study.NEWS2: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for August 14, 2019.NEWS3: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for August 14, 2019.NEWS4: 8 Stocks That Have Paid a Dividend for 125 (or More) Consecutive Years.NEWS5: 8 Stocks That Have Paid a Dividend for 125 (or More) Consecutive Years.NEWS6: Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis.NEWS7: 8 Stocks That Have Paid a Dividend for 125 (or More) Consecutive Years.NEWS8: How one Boston startup rode the diabetes investment wave to raise $126M.
2019-08-14: NEWS1: Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?.NEWS2: Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?.NEWS3: Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study.NEWS4: Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study.NEWS5: Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?.NEWS6: Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study.NEWS7: Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health.
2019-08-15: NEWS1: The Top Pharma Stocks for 2019.NEWS2: Agios Rides High on Tibsovo Sales Amid Acute Competition.NEWS3: Agios Rides High on Tibsovo Sales Amid Acute Competition.NEWS4: Agios Rides High on Tibsovo Sales Amid Acute Competition.
2019-08-16: NEWS1: How AbbVie Plans To Take On Pfizer, Lilly — And Kick Its Humira Habit.NEWS2: Pharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY.NEWS3: Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe.NEWS4: Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe.NEWS5: Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe.

Answer: Rise